Form 1
Evaluation form 1 is used if the treatment is a new adjuvant or neoadjuvant therapy or if it's a new, potentially curative treatment
ESMO-MCBS Online Tutorials
These ESMO-MCBS video tutorials below provide an overview of the scale and scoring methodology with detailed examples
The ESMO-MCBS is a validated and reproducible tool based on a rational, structured and consistent approach to the interpretation of published clinical trial data that can be used to determine an agent's relative grading in relation to its anticipated clinical benefit in a specific setting.
To find out more, please watch the introduction video below:
Form 2a
Evaluation form 2a is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication either:
- had a primary endpoint of overall survival, or
- had a primary endpoint of progression-free survival and a secondary endpoint of OS with mature data showing a significant OS benefit versus the control arm of the trial
Form 2b
Evaluation form 2b is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of progression free survival
Form 2c
Evaluation form 2c is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of quality of life or response rate, or if it was a non-inferiority study
Form 3
Evaluation form 3 is used for single-arm studies in orphan diseases or those with a high unmet need, where the clinical trial that led to its licensed indication had a primary endpoint of progression-free survival or overall response rate. Overall response rate includes all patients that had either a complete or partial response to treatment
Quality of Life Checklist
The QoL Checklist is used to evaluate ESMO-MCBS score adjustments based on quality of life.